Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Research & Development (2016 - 2025)

Historic Research & Development for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $22.6 million.

  • Vanda Pharmaceuticals' Research & Development rose 3449.57% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.1 million, marking a year-over-year increase of 2682.76%. This contributed to the annual value of $74.4 million for FY2024, which is 311.37% down from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Research & Development is $22.6 million, which was up 3449.57% from $22.0 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Research & Development peaked at $35.7 million during Q1 2025, and registered a low of $16.1 million during Q1 2021.
  • Moreover, its 5-year median value for Research & Development was $19.8 million (2024), whereas its average is $20.7 million.
  • Its Research & Development has fluctuated over the past 5 years, first plummeted by 3321.8% in 2023, then skyrocketed by 6881.91% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Research & Development (Quarter) stood at $19.3 million in 2021, then dropped by 4.54% to $18.5 million in 2022, then soared by 31.89% to $24.3 million in 2023, then fell by 18.48% to $19.8 million in 2024, then grew by 13.72% to $22.6 million in 2025.
  • Its Research & Development was $22.6 million in Q3 2025, compared to $22.0 million in Q2 2025 and $35.7 million in Q1 2025.